Bladder Cancer Coverage from Every Angle

Peter H. O’Donnell, MD, on Pembrolizumab for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Posted: Wednesday, July 7, 2021

Peter H. O’Donnell, MD, of The University of Chicago, discusses implications of results from the KEYNOTE-052 trial, which showed the benefit of first-line pembrolizumab for cisplatin-ineligible patients with advanced disease, his own clinical experience with the therapy, and what the future of this treatment might be.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.